Effect of dronedarone on cardiovascular events in atrial fibrillation.

By S. Hohnloser, H. Crijns, Martin van Eickels, C. Gaudin, R. Page, C. Torp-Pedersen, S. Connolly. New England Journal of Medicine, 2009

1,126 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ddd72e204c00836cb5d3e46f4abe306079955782

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Gerhard Hindricks
2. Gregory Y. H. Lip
3. A. Goette
4. Paulus Kirchhof
5. Ulrich Schotten

Citations in the corpus

• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010, background): “Specifically, dronedarone appears to have a low potential for proarrhythmia.(95,99) Dronedarone was shown in two large”
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “2 Dronedarone Dronedarone maintains sinus rhythm, reduces ventricular rate, and prevents cardiovascular hospitalizations (mostly due to AF) and cardiovascular death in patients with paroxysmal or persistent AF or flutter who had at least one relevant cardiovascular comorbidity.(583,588,656) Dronedar”